As you may have seen in the news, a new study was recently released, renewing the debate on the relationship between hormone therapy (HT) and breast cancer. Conducted by the Collaborative Group on Hormonal Factors in Breast Cancer, the study looked at data from 58 other studies, which, taken together, included over 108,000 cases of invasive breast cancer.
Results showed that the relative risks were greater for women who used estrogen plus progestin than for estrogen alone; that risks were greater in current than in past users; and that the risks increased with duration of use in current and past users.
How much might it increase the risk? Five years of HT starting at age 50 translates into about one extra case of cancer per year for every 50 women taking a combination of estrogen and progestin daily; an additional case for every 70 women taking estrogen plus intermittent progestin, and an additional case in 200 women using estrogen only. In women using the treatments for 10 years, the number would be twice that. No increased risk was found for women who used vaginal estrogen.
The internet loves an alarmist headline, but there are good reasons not to panic. First, the results show association, not causation (an important distinction). Second, as NAMS points out, the report is based on old prescribing practices for HT, including oral estrogens and regimens that are now rarely used because we know their adverse effects. So the report doesn’t tell us anything about the risks associated with current prescribing practices. Finally, the absolute risks are low and could be the result of a bias in the research.
According to NAMS, the WHI randomized trials still provide the best estimate of absolute risk for breast cancer associated with the use of HRT—six additional cases per 10,000 women/year.
An important finding in the study was that obesity is itself a sufficient risk factor for developing breast cancer so that HT did not appear to add risk. That is, being obese raises the risk of breast cancer as much or more as HT, depending on other factors—like age and specifics of HT.
For me, the findings of the study just confirm my belief that treatment for menopausal symptoms needs to be customized for each woman, given her risk factors, symptoms, and preferences. For example, the study talks about an “increased” risk for younger women who are on HT because they’ve gone through menopause early. But they have no more risk of developing breast cancer than their premenopausal friends, and taking HT until the natural age of menopause can offset the risk of developing other serious conditions.
I recommend being up on the latest information on health-related issues, but nothing beats talking to a well-informed doctor about what is right for you.
Dr. Barb DePree, M.D., has been a gynecologist and women’s health provider for almost 30 years and a menopause care specialist for the past ten. Read more about and from her here.